Levofloxacin pharmacokinetics and pharmacodynamics in patients with severe burn injury

被引:25
作者
Kiser, Tyree H.
Hoody, Dorie W.
Obritsch, Marilee D.
Wegzyn, Colleen O.
Bauling, Paulus C.
Fish, Douglas N.
机构
[1] Univ Colorado, Hlth Sci Ctr, Sch Pharm, Dept Clin Pharm, Denver, CO 80262 USA
[2] Univ Colorado Hosp, Dept Pharm Serv, Denver, CO USA
[3] Univ Oklahoma, Hlth Sci Ctr, Coll Pharm, Dept Pharm Clin & Adm Sci, Tulsa, OK USA
[4] Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA
关键词
D O I
10.1128/AAC.01466-05
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Levofloxacin pharmacokinetics were studied in 11 patients with severe burn injuries. Patients (values are means standard deviations; age, 41 +/- 17 years; weight, 81 +/- 12 kg; creatinine clearance, 114 +/- 40 ml/min) received intravenous levofloxacin at 750 mg (n = 10 patients) or 500 mg (n = one patient) once daily. Blood samples were collected on day I of levofloxacin therapy; eight patients were studied again on days 4 to 6. The pharmacodynamic probability of target attainment (PTA) was evaluated by Monte Carlo simulation. Mean systemic clearance, half-life, and area under the concentration-time curve over 24 It after levofloxacin at 750 mg were 9.0 +/- 3.2 liters/h, 7.8 +/- 1.6 h, and 93 +/- 31 mg center dot h/liter, respectively. There were no differences in pharmacokinetic parameters between day I and day 4; however, large intrapatient and interpatient variability was observed. Levofloxacin pharmacokinetics in burned patients were similar to those reported in other critically ill populations. Levofloxacin at 750 mg achieved > 90% PTA for gram-negative and gram-positive pathogens with MICs of <= 50.5 mu g/ml and MICs of <= 1 mu g/ml, respectively. However, satisfactory PTA was not obtained with less-susceptible gram-negative organisms with MICs of 1 mu g/ml or any organism with a MIC of >= 2 mu g/ml. The results of this study indicate that levofloxacin should be administered at 750 mg/day for treatment of systemic infections in severely burned patients. However, even 750 mg/day may be inadequate for gram-negative organisms with MICs of 1 to 2 mu g/ml even though they are defined as susceptible. Alternative antibiotics or treatment strategies should be considered for infections due to these pathogens.
引用
收藏
页码:1937 / 1945
页数:9
相关论文
共 36 条
  • [1] BJERKNES R, 1990, BLOOD CELLS, V16, P127
  • [2] PATHOPHYSIOLOGY AND PHARMACOKINETICS FOLLOWING BURN INJURY
    BONATE, PL
    [J]. CLINICAL PHARMACOKINETICS, 1990, 18 (02) : 118 - 130
  • [3] Fluconazole pharmacokinetics in burn patients
    Boucher, BA
    King, SR
    Wandschneider, HL
    Hickerson, WL
    Hanes, SD
    Herring, VL
    Canada, TW
    Hess, MM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (04) : 930 - 933
  • [4] Clinical pharmacokinetics of piperacillin-tazobactam combination in patients with major burns and signs of infection
    Bourget, P
    LesneHulin, A
    LeReveille, R
    LeBever, H
    Carsin, H
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (01) : 139 - 145
  • [5] Penetration of levofloxacin into skin tissue after oral administration of multiple 750 mg once-daily doses
    Chow, AT
    Chen, A
    Lattime, H
    Morgan, N
    Wong, F
    Fowler, C
    Williams, RR
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2002, 27 (02) : 143 - 150
  • [6] Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers
    Chow, AT
    Fowler, C
    Williams, RR
    Morgan, N
    Kaminski, S
    Natarajan, J
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (07) : 2122 - 2125
  • [7] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [8] Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men
    Craig, WA
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) : 1 - 10
  • [9] BURNS
    DEMLING, RH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (22) : 1389 - 1398
  • [10] Relationship between fluoroquinolone area under the curve:minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia
    Drusano, GL
    Preston, SL
    Fowler, C
    Corrado, M
    Weisinger, B
    Kahn, J
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (09) : 1590 - 1597